3D printed tablets loaded with polymeric nanocapsules: An innovative approach to produce customized drug delivery systems by Beck, RCR et al.
 1 
3D printed tablets loaded with polymeric nanocapsules: an innovative 
approach to produce customized drug delivery systems 
 
Beck, R. C. R.a,b*, Chaves, P. S.a; Goyanez, A.c, Vukosavljevic, B.d, Buanz, 
A.b, Windbergs, M.d,e, Basit, A. W. b,c, Gaisford, Sb,c. 
 
a School of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, 
RS, Brazil 
b UCL School of Pharmacy, University College London, London, UK  
c FabRx Ltd., Ashford, Kent, UK 
d Helmholtz Centre for Infection Research (HZI) and Helmholtz Institute for 
Pharmaceutical Research Saarland (HIPS), Department of Drug Delivery, 
Saarbruecken, Germany 
e Institute of Pharmaceutical Technology and Buchmann Institute for 
Molecular Life Sciences, Goethe University, Frankfurt am Main, Germany 
 
*Corresponding author: Ruy Carlos Ruver Beck (ruy.beck@ufrgs.br) 
Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul 
Av. Ipiranga, 2752, 90610-000, Porto Alegre, RS, Brazil 
 2 
Abstract 
The generation of multi-functional drug delivery systems, namely solid dosage 
forms loaded with nano-sized carriers, remains little explored and is still a 
challenge for formulators. For the first time, the coupling of two important 
technologies, 3D printing and nanotechnology, to produce innovative solid 
dosage forms containing drug-loaded nanocapsules was evaluated here. 
Drug delivery devices were prepared by fused deposition modelling (FDM) 
from poly(ε-caprolactone) (PCL) and Eudragit® RL100 (EUD) filaments with or 
without a channelling agent (mannitol). They were soaked in deflazacort-
loaded nanocapsules (particle size: 138 nm) to produce 3D printed tablets 
loaded with them, as observed by SEM. Drug loading was improved by the 
presence of the channelling agent and a linear correlation was obtained 
between the soaking time and the drug loading (r2 = 0.9739). Moreover, drug 
release profiles were dependent on the polymeric material of tablets and the 
presence of the channelling agent. In particular, tablets prepared with a 
partially hollow core (50% infill) had a higher drug loading (0.27 % w/w) and 
faster drug release rate. This study represents an original approach to convert 
nanocapsules suspensions into solid dosage forms as well as an efficient 3D 
printing method to produce novel drug delivery systems, as personalised 
nanomedicines. 
Keywords: 3D printing, drug delivery, fused deposition modelling, 
nanocapsules, nanotechnology. 
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1. Introduction 
Three-dimensional (3D) printing is an additive manufacturing technology 
characterized by a single process to combine different materials to build 
objects from a 3D model, which can circumvent the use of different unit 
operations (Frazier, 2014; Jonathan and Karim, 2016). 3D printing comprises 
a range of different technologies, such as stereolithography (SLA), fused 
deposition modelling (FDM), pressure-assisted microsyringes (PAM) and 
selective laser sintering (SLS).  
Its application in the development of drug delivery systems has been recently 
described to produce fast-disintegrating tablets (Yu et al., 2009), time-
controlled release tablets (Goyanes et al., 2015a, Pietrzak et al., 2015, Wang 
et al., 2016), multi-layer caplets (Goyanes et al., 2015b), multi-active solid 
dosage forms (Khaled et al., 2014), microneedles (Boehm et al., 2014, 
Kochhar et al., 2012), implants (Water et al., 2015) and topical drug delivery 
devices (Goyanes et al., 2016). 
Among the available techniques, FDM printing has some important 
advantages, such as low cost, no need for organic solvents, the feasibility of 
blending of drugs and polymeric materials in a prior hot-melt extrusion step 
(Jonathan and Karim, 2016), the ability to manufacture of multidrug devices 
(Goyanes et al., 2015b), the modulation of drug release profiles through 
shape and density (Goyanes et al., 2014), the preparation of devices from 
FDA GRAS (Generally Recognized as Safe) raw materials (Pietrzak et al., 
2015, Melocchi et al., 2016) as well as the feasibility to produce customizable 
drug delivery devices for personalised medicine (Choonara et al., 2016, 
Tucker et al., 2016). Personalised medicine covers the individualisation of the 
drug therapy, dosing intervals, drug combinations and drug release rate, 
taking into account an individual’s differences in genome, metabolic functions, 
patient groups, coexisting diseases and the need of multiple drugs (Alomari et 
al., 2015, Tucker et al., 2016).  
On the other hand, nanotechnology has been an important tool for the 
development of novel drug delivery systems (Bobo et al., 2016) and has great 
potential to transform medicine, including the realisation of personalised 
medicines (Herrmann and Rösslein, 2016). Among the reported drug 
nanocarriers, polymeric nanocapsules have gained special attention due to 
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their ability to control the drug release profile and their good stability in 
biological fluids (Pohlmann et al., 2013). Moreover, drug-loaded nanocapsules 
have been reported to improve the efficacy of drugs, their aqueous solubility 
and chemical stability, their oral bioavailability as well as to overcome 
biological barriers (Frank et al., 2015, Friedrich et al., 2015).  
Polymeric nanocapsules are composed of an oily core surrounded by a thin 
polymeric wall stabilized by a surfactant (Pohlmann et al., 2013). They are 
obtained as liquid suspensions and can be physically stable for months, 
although they show a high risk of microbiological contamination for long-term 
storage due to their high water content (Beck et al., 2012). Some efforts have 
been carried out to produce solid forms containing nanocapsules to overcome 
drawbacks regarding microbiological contamination, physical stability, storage 
and shipping, including spray-drying (Beck et al., 2012), freeze-drying 
(Schaffazick et al., 2003) and wet granulation techniques (Friedrich et al., 
2010a). However, there is still one report on the production of tablets 
containing drug-loaded polymeric nanocapsules (Friedrich et al., 2010b), 
which were produced by wet granulation reaching a maximum drug loading of 
0.083 % (w/w). No report on the formulation of spray-dried or freeze-dried 
drug-loaded polymeric nanocapsules as tablets is available. In addition, 
tablets containing Newcastle disease virus loaded in naturally occurring 
casein micelles, called nanocapsules, were previously formulated by moulding 
for veterinary use (Wambura, 2011). 
To the best of our knowledge, there is no report on the development of 3D 
printed dosage forms containing drug nanocarriers, although the use of non-
polymeric nanoparticles in the production of 3D printed materials by SLA 
printing has been reported in the literature for purposes other than drug 
delivery (Zhu et al., 2016, Pawar et al., 2016).  
In this scenario, this study was designed to conjugate 3D printing and 
nanotechnology in the development of tablets containing polymeric 
nanocapsules, as personalised medicines, to tailor their drug dose and drug 
release profile. 3D printed tablets loaded with nanocapsules were prepared 
from Eudragit RL100® or poly(ε-caprolactone) polymers, as aqueous 
swellable and non-swellable polymers, respectively. The manufacturing 
process is detailed in Figure 1. Polymeric filaments were prepared by hot met 
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extrusion (HME), which were then FDM 3D printed to create the delivery 
devices. Drug-loading was achieved by soaking the printed devices in a 
nanoparticle liquid suspension. The effect of the type of the main polymeric 
material of the tablets, the presence of a channelling agent and the infill 
percentage on their drug loading and drug release profiles were evaluated. 
Deflazacort was used as a model drug.  
 
Please insert Figure 1 about here. 
 
2. Material and Methods 
2.1. Materials 
Eudragit RS100® and RL100® were obtained from Evonik Industries 
(Darmstadt, Germany). Polysorbate 80 was acquired from Sigma-Aldrich 
(Poole, UK). Miglyol 812 N was kindly donated by Cremer (Witten, Germany). 
Deflazacort was supplied by Fagron (São Paulo, Brazil). Poly(ε-caprolactone), 
50,000 Da MW, as powder (CapaTM 6506), was kindly donated by Perstop 
(Cheshire, UK). Acetone (Fisher Chemicals) was obtained from Fisher 
Scientifics (Loughborough, UK). Mannitol (Alfa Aesar®) and PEG6000 were 
purchased from Fisher Scientifics (Loughborough, UK) and Merck (Darmstadt, 
Germany), respectively. Microcrystalline cellulose (Avicel PH301®, FMC 
Biopolymer) was supplied by IMCD (Sutton, UK). Triethyl citrate was acquired 
from Sigma-Aldrich (St. Louis, USA). HPLC grade acetonitrile was purchased 
from Fisher Scientifics (Loughborough, UK). All other chemicals and solvents 
were of analytical grade and were used as received.  
 
2.2. Methods 
2.2.1. Preparation and characterization of the filaments 
Filaments were prepared by hot-melt extrusion (HME). Four different filaments 
were produced with a swellable polymer (Eudragit RL100® - ERL) or a non-
swellable polymer [Poly(ε-caprolactone) – PCL], as the main polymeric 
compound, with or without mannitol as a channelling agent. For tablets 
prepared without the channelling agent, microcrystalline cellulose was used 
instead of mannitol, due to its low water solubility. Triethyl citrate was used as 
a plasticizer and PEG 6000 as a hydrophilic lubricant to facilitate the extrusion 
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process. The composition of the four different filaments produced is detailed 
in Table 1. The components were weighed and mixed using mortar and pestle 
for 5 min. Afterwards, the mixture (40 g) was fed in a single-screw hot-melt 
extruder (Noztek Pro, Noztek, Shoreham, UK). The extrusion was carried out 
through a nozzle die of 1.5 mm (ERL filaments) or 2.0 mm diameter (PCL 
filaments). The extruding temperature was set to 110 ± 5 °C and 65 ± 5 °C for 
ERL and PCL filaments, respectively. The diameter of the filament was 
measured with a digital Calliper (Fowler High Precision, Auburndale, USA) at 
different positions along the filament in order to assure a diameter between 
1.65 ± 0.05 mm.  
 
Please insert Table 1 about here. 
 
All filaments and their respective physical mixtures (PM-ERL-M, PM-ERL-A, 
PM-PCL-M and PM-PCL-A) were analysed by Differential Scanning 
Calorimetry (DSC). Analyses were performed with a Q2000 DSC (TA 
Instruments LLC, USA) at a heating rate of 10 °C/min. Indium (Tm= 156.6 °C, 
ΔHf = 28.71 J/g) was used to calibrate the cell constant and enthalpy. 
Nitrogen was used as a purge gas at a flow rate of 50 mL/min. Data were 
collected and analysed using TA Instruments Advantage software in the range 
between 25 °C and 250 °C. TA aluminium pans and pin-holed hermetic lids 
(Tzero) were used with an average sample mass between 8 and 10 mg. 
Thermogravimetric analysis (TGA) was performed with a Discovery Series 
TGA, (TA instruments LLC, USA). Samples were heated at 10 °C/min in open 
aluminum pans, using Nitrogen as a purge gas (flow rate of 25 mL/min). Data 
were analyzed using TA Instruments Trios software. The percentage mass 
loss and/or onset temperature were calculated. 
2.2.2. Preparation and characterization of the 3D printed delivery devices 
Delivery devices were produced with the four different filaments (ERL-M, 
ERL-A, PCL-M and PCL-A) using a commercial FDM 3D printer (MakerBot 
Replicator 2, MakerBot Inc, USA). The printing process was based on a 
template previously reported by Goyanes and co-workers (2014), comprising 
a disk-shaped tablet with a mean diameter of 10.0 mm and a height of 3.60 
mm. The 3D object was designed with MakerWare Software (v.2.2.2). The 
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printing process was carried out at an extrusion temperature of 170 °C and 95 
°C for the delivery devices prepared from the ERL and PCL filaments, 
respectively. The following printing parameters were used: speed while 
extruding (90 mm/s), speed while traveling (150 mm/s), number of shells (2), 
infill percentage (100%), and layer thickness (0.20 mm). At least 10 devices 
from each filament were prepared and analysed. In order to evaluate the 
influence of the infill percentage, devices from the filament ERL-M were also 
prepared with 50 % of infill percentage. 
The mean weight of the delivery devices was evaluated weighing separately 
10 devices using a calibrated analytical balance (CPA225D model, Sartorius, 
Gottingen, Germany). Their mean diameter and mean height were measured 
using a digital Calliper (Fowler High Precision, Auburndale, USA). The 
diameter of each device was measured in two different parallels (horizontal 
and vertical) and their mean values were considered.  
2.2.3. Preparation and characterization of deflazacort-loaded polymeric 
nanocapsules 
Nanocapsules were prepared by interfacial deposition of Eudragit RS 100®, 
(Fontana et al., 2014). An organic phase containing polymer (EUD, 0.5g), 
Miglyol 812 N (0.83 mL), and deflazacort (25 mg) in acetone (134 mL) was 
prepared under magnetic stirring at room temperature. Afterwards, this 
organic phase was injected into an aqueous phase (267 mL) containing 
polysorbate 80 (0.385 g) under magnetic stirring at room temperature (25 ± 5 
°C). This dispersion was left under magnetic stirring for 10 min followed by the 
evaporation of the acetone and most of the water content under reduced 
pressure at 50 °C to form a concentrated aqueous dispersion (Rotavapor RC 
900, KNF LAB, Balterswil, Switzerland). The final volume was set to 50 mL to 
reach a deflazacort concentration of 0.5 mg/mL. Three independent batches 
were prepared and characterized. The batches were kept at room 
temperature (25 ± 5 °C) and protected from light. This formulation was named 
as DFZ-ENC. After preparing, the particle size distribution, zeta potential, drug 
content and drug encapsulation efficiency were evaluated. 
Volume-weighted mean diameters (D4,3) and polydispersity (Span) (n=3) were 
analysed by laser diffraction (LD) (Mastersizer 3000, Malvern Instruments 
Ltd., UK), dropping the sample directly into the compartment disperser 
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containing ultrapure water (150 mL). Mean particle size and polydispersity 
index (PDI) (n=3) were also measured using (DLS) (ZetaSizer Nano ZS, 
Malvern Instruments Ltd., UK) after the dilution of the suspensions (20 µL) in 
previously filtered (Millex-HA filter, 0.45 µm, Merck Millipore, Darmstadt, 
Germany) ultrapure water (10 mL). Zeta potential was measured by 
electrophoretic mobility (ZetaSizer Nano ZS, Malvern Instruments Ltd., UK). 
Samples were diluted (1:500 v/v) in NaCl solution (10 mM) previously filtered 
(Millex-HA Filter, 0.45 µm, Merck Millipore, Darmstadt, Germany). 
Drug content was measured (n=3) by liquid chromatography (LC), according 
to a method previously described (Rigo et al., 2016) with some modifications. 
The chromatographic system consisted of an Eclipse Plus RP-18 column (150 
mm x 4.6 mm, 5 µm, Agilent Technologies, Santa Clara, USA) and an Agilent 
LC instrument (1200 series, G1311A Quaternary Pump, G1329A 
Autosampler, and G1314B Variable Wavelenght Detector, Agilent 
Technologies, Santa Clara, USA). The mobile phase (at a flow rate of 0.8 
mL/min) was composed of acetonitrile/water (80:20%, v/v), the volume of 
injection was 100 µl, and DFZ was detected at 244 nm. DFZ-ENC suspension 
(200 L) was transferred to a 10 mL volumetric flask. The sample aliquot was 
completely dissolved adding acetonitrile (8 mL) followed by adjusting the 
volume with the same solvent. The diluted sample was filtered (0.45 µm, 
Millipore® filter) and analysed by LC. Encapsulation efficiency was calculated 
based on the difference between total drug and free drug content in the 
ultrafiltrate. The ultrafiltrate was obtained by ultrafiltration/centrifugation 
technique (Ultrafree-MC 10,000 MW, Millipore, Billerica, USA) at 4,120 g for 
10 min.  
In-vitro drug release from DFZ-ENC was evaluated (n=3) using the dialysis 
bag method (Rigo et al., 2016). Water containing polysorbate 80 at 2 % (w/v) 
was used as medium at 37 °C in order to maintain the sink conditions. The 
dialysis bag containing 1 mL of the sample (0.5 mg/mL) was placed in a 250-
mL flask filled with release medium (200 mL) under constant stirring (70 ± 10 
rpm). Aliquots (1 mL) of the external medium were withdrawn at 
predetermined time intervals, and replaced by an equal volume of fresh 
medium. The withdrawn sample was filtered (0.45-µm filter) and DFZ was 
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assayed by liquid chromatography according to the methodology described 
above, using 20 µL as injection volume.  
 
 
 
2.2.4. 3D printed tablets loaded with polymeric nanocapsules 
2.2.4.1. Preparation 
3D printed tablets were loaded with polymeric nanocapsules by soaking the 
3D printed devices in the DFZ-ENC suspension (2 mL/device) for 24h at room 
temperature. Afterwards, the 3D printed tablets were removed and dried at 30 
°C for 24 h. They were stored at room temperature and protected from light 
until analysis. At least 6 tablets were prepared for each formulation. The 
influence of the soaking time (4, 12 and 24 h) was evaluated.  
 
2.2.4.2 Physical Characterization 
Physical dimensions (diameter and height) and mean weight of 3D printed 
tablets were assessed as previously described for the delivery devices.  
 
2.2.4.3 Swelling and Erosion Index 
For swelling and erosion experiments, three devices from each formulation 
were weighed and placed into individual glass flasks. DFZ-ENC suspension (2 
mL) was added to each flask. After 24 h of soaking, the tablets were carefully 
withdrawn with tweezers. The weights of the hydrated tablets were recorded. 
Afterwards, the tablets were placed in Petri dish glasses at 30 °C for 24 h to 
remove the water and to reach a constant mass. Tablets were reweighed. The 
swelling and the erosion index for each formulation was calculated according 
to Equations 1 and 2 (Groves and Chaw, 2015), respectively: 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 (%)  =  
𝑀𝑡 − 𝑀𝑟
𝑀𝑟
 ×  100  (1) 
Where Mt is the mass of the hydrated tablet after the soaking time (g) and Mr 
is the mass of the swollen tablet after it has been dried (g).  
𝐸𝑟𝑜𝑠𝑖𝑜𝑛 𝑖𝑛𝑑𝑒𝑥 (%)  =  
𝑀0 − 𝑀𝑟
𝑀0
 ×  100  (2) 
Where M0 is the mass of the dry tablet (device) before swelling (g) and Mr is 
the mass of the swollen tablet after it has been dried (g). 
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2.2.4.4 Drug content, drug loading and thermal analysis 
Each tablet was placed in a sample glass flask containing acetonitrile (10 mL, 
n = 3). The flasks were sonicated for 5 or 20 minutes (EUD or PCL tablets, 
respectively). All the content of the sample flask was quantitatively transferred 
to a 25 mL volumetric flask, which was filled to volume with mobile phase. The 
sample solution was filtered through 0.45-µm membrane (PTFE filters, 13 
mm, Perkin Elmer, China) for the LC analyses, according to the details 
described earlier (Section 2.2.3). The method was specific, linear (y= 245.31x 
+ 27.58, r=0.9999, n=3) in the range of 2.00-20.00 µg/mL, and precise 
(SD=0.91% and 2.44% for intra-day and inter-day precision). Accuracy was 
100.35 ± 1.68 %. Retention time was 2.4 min for deflazacort. Drug content 
was calculated as the amount of drug per tablet (as mg/tablet), whereas the 
drug loading was calculated from the ratio between the amount of drug and 
the final tablet mass (as %). Thermal analyses were carried out by TGA and 
DSC, as previously described for the filaments (Section 2.2.1). 
 
2.2.4.5 Confocal Raman microscopy 
Confocal Raman microscopy (CRM) measurements were performed with a 
WITec alpha 300R+ (WITec GmbH, Ulm, Germany). The excitation source 
was a monochromatic diode laser (excitation wavelength 532 nm) which was 
adjusted to a power of 20 mW before the objective (Epiplan Neofluar, Zeiss, 
Germany, 50x magnification, N.A. 0.8).Signals from out-of-focus regions were 
rejected by a confocal 50-μm pinhole. Raman spectra of the pure compounds 
were acquired with 10 accumulations and an integration time of 0.5 s. Image 
scans of the samples were recorded with an integration time of 0.5 s and a 
step size was 0.5 µm along the x- and y-axis. Spectra were background 
subtracted, normalized, and finally converted into false color images using the 
WITec Project Plus software (WITec GmbH, Ulm, Germany). In these images, 
pixels assigned to mannitol and MCC spectra are depicted in yellow, while 
ERL and PCL appear in yellow. 
 
2.2.4.6 Scanning Electron Microscopy 
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SEM analyses were carried out using a Jeol JSM-6360 Scanning Electron 
Microscope (Jeol, Tokyo, Japan) at different magnifications. Analyses were 
carried out at the Centro de Microscopia e Microanálise (UFRGS, Porto 
Alegre, Brazil). Tablet surfaces and their inner compartments were analysed 
after longitudinal breaking. Samples were analysed after they had been gold 
sputtered (Jeol Jee 4BSVG-IN, Tokyo, Japan). 
2.2.4.7 In-vitro drug release 
In-vitro drug release profiles from 3D printed tablets were evaluated (n=3) 
using the dialysis bag method, as previously described (Section 2.2.3). Each 
tablet was inserted in the dialysis bag containing the release medium (1 mL 
water with polysorbate 80 at 2% w/v). In order to evaluate the influence of the 
polymeric device (PCL or ERS), the presence of the channelling agent and 
the infill rate, release data (n = 3) were modelled (MicroMath Scientist for 
WindowsTM) according to a monoexponential equation (Equation 3) (Cruz et 
al., 2006). Half-life time (t1/2) was calculated according to Equation 4. Data 
corresponding to the drug release curve between 0 and 60% were fitted to the 
Power Law model (Equation 5) to understand the mechanism of drug release 
from the tablets (Siepmann and Peppas, 2012). These equations are 
described below: 
𝐶  =  𝐶0𝑒
−𝑘𝑡   (3) 
where C is the concentration of drug release at time t (h), C0 is the initial 
concentration of the drug and k (h-1) is the constant release. 
 𝑡1
2⁄
 =  
0.693
𝑘
   (4) 
where t1/2 is the time (h) corresponding to 50% of drug release and k (h-1) is 
the constant release calculated for each formulation according to Equation 3. 
𝐶 =  𝑎𝑡𝑛    (5) 
where C is the fraction of DFZ released at time t (h), a is the constant 
incorporating structural and geometric characteristics of the dosage form, and 
n is the release exponent,  which is indicative of the drug release mechanism. 
 
2.2.4.8 In-vitro nanoparticle release 
The qualitative release of nanoparticles from the 3D printed tablets containing 
nanocapsules was evaluated by DLS (ZetaSizer Nano ZS, Malvern 
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Instruments Ltd., UK). Each 3D printed tablet was placed in a sample flask 
containing ultrapure water (20 mL), as the release medium. Experiments were 
carried out for 24 h under magnetic stirring. After 1, 4 and 8 h the whole 
medium was withdrawn and replaced by a fresh medium. The medium 
withdrawn at each time as well as the medium after 24 h of experiment were 
filtered (0.45 µm, Millipore® filter) and analysed by DLS. 
 
2.2.5 Statistical analysis 
Statistical analyses were carried out by one-way and two-way ANOVA, 
followed by Tukey’s test, as post-hoc multiple comparisons, at p-value ≤ 0.05 
(GraphPad Prism software, version 7.0b, GraphPad Software, Inc, USA). 
 
3. Results and Discussion 
3.1. PCL and EUD polymeric filaments 
All filaments were successfully prepared by hot-melt extrusion with a diameter 
between 1.60 and 1.70 mm. After preparation filaments were evaluated by 
DSC. DSC thermograms are shown in Figure 2. Figure 2A shows the 
thermograms for the main components of the filaments (Eudragit RL100®, 
PCL, Mannitol, PEG6000 and microcrystalline cellulose). The glass transition 
temperature of EUD RL100® was found to be 59.7 °C, confirming a previous 
report by Shinde and co-workers (2012). PCL showed a broader endothermic 
peak at 61.1 °C, representing its melting point, which corresponds to its 
known semi-crystalline form (Pohlmann et al., 2013). PEG 6000 and mannitol 
showed sharp and prominent endothermic peaks at 62.2 °C and 168.5 °C, 
respectively, representing their melting points (Rowe et al., 2009). For 
microcrystalline cellulose a broad endothermic event up to about 150 °C was 
observed, indicating water loss, which corresponded to a mass loss in the 
TGA analysis of about 4.5%. TGA data showed thermal degradation starting 
at about 280 °C (data not shown). Taking into account these data, extruding 
and printing temperatures were chosen to be below the degradation of any of 
the components. Figures 2B and 2C show the thermograms for the EUD and 
PCL filaments and their physical mixtures, respectively. EUD filaments 
containing mannitol (Figure 2B) exhibited the presence of endothermic peaks 
at 59.9 °C and 167 °C, corresponding to the presence of PEG 6000 and 
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mannitol, respectively, while the filaments prepared with microcrystalline 
cellulose showed an endothermic peak at 55.4 °C, corresponding to the 
presence of PEG 6000. Differences in the thermal behaviour were not found 
between the EUD filaments and their respective physical mixtures, showing 
their crystalline state was not changed during HME processing. Similar 
behaviour was observed for PCL filaments (Figure 2C), whose thermograms 
showed the presence of a broad and prominent peak about 61 °C, 
corresponding to the overlapping of the melting points of PCL and PEG 6000 
in the filaments due to their semi-crystalline or crystalline state, regardless of 
the presence of mannitol or microcrystalline cellulose. Samples containing 
mannitol (FIL-PCL-M and PM-PCL-M) showed an additional sharp and 
prominent endothermic peak at about 168 °C, representing to its melting point 
(Rowe, 2009) and confirming its crystalline state to be the stable beta form in 
the starting material.  
 
Please insert Figure 2 about here. 
 
3.2. 3D printing of the delivery devices 
All the filaments could be printed using FDM to produce the 3D printed 
delivery devices, regardless of the type of the polymer or the presence of the 
channelling agent. Table 2 shows their properties, such as mean weight, 
diameter and height. Their physical dimensions were in agreement with the 
digital template (10 and 3.60 mm for diameter and height, respectively), with 
less than 10% of variation. Eudragit RL100® tablets were previously reported 
by Pietrzak and co-workers (2015) for theophylline extended release. They 
were prepared at a similar extruding temperature, but without any channelling 
agent. Moreover, to the best of our knowledge, there is no previous report on 
the preparation of PCL tablets by 3D printing, as drug delivery systems. 
Goyanes and co-workers (2016) obtained PCL filaments from a higher 
molecular weight polymer (80,000 Da), from solvent casted films, in the 
development of anti-acne topical drug delivery systems, which were not able 
to be printed into 3-dimensional objects.  
 
Please insert Table 2 about here. 
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In order to evaluate the influence of the infill percentage on the preparation of 
3D printed tablets loaded with nanocapsules, delivery devices were also 
prepared with 50% infill percentage using the filament ERL-M (ERL-M-50%). 
They showed mean weight, diameter and height of 0.2513 ± 0.0111 g, 9.68 ± 
0.15 mm and 3.82 ± 0.06 mm, respectively, similar to that of tablets prepared 
with 100% of infill percentage, except the mean weight. The lower the infill 
percentage, the lower the mean weight. From these data, all the 3D printed 
devices were selected for further studies on their loading with polymeric 
nanocapsules.  
 
3.3. Deflazacort-loaded nanocapsules 
Deflazacort-loaded nanocapsule suspensions, as a model of nanoparticle 
suspension, had a milky bluish aspect with a Tyndal effect. The particle size 
distribution in the nanoscale was confirmed by laser diffraction (Figure 3a), 
with 90% (d90) of the particles smaller than 0.2843 ± 0.0071 µm. In addition, 
the D(4,3) value was 0.125 ±  0.003 µm (SPAN: 2.9). The absence of any 
microparticle population confirms the suitable composition of these 
nanocapsules. The Z-average size was confirmed by DLS (Figure 3b) as 138 
± 1 nm, with a narrow particle size distribution (polydispersity index: 0.10 ± 
0.02) (n = 3). The particles showed a cationic surface with a zeta potential of 
+6.87 ± 0.44 mV, explained by the cationic properties of their polymeric wall 
(Eudragit RS 100®). The drug content and encapsulation efficiency were 
0.458 ± 0.003 mg/mL and 80.8%, respectively. No aggregation or drug 
degradation occurred during storage at room temperature (1 month). These 
properties are in agreement with previous reports regarding Eudragit RS100 
nanocapsules prepared by the interfacial deposition of preformed polymer  
(Fontana et al., 2014, Katzer et al., 2014) as well as deflazacort 
nanoencapsulation (Rigo et al., 2016). Obtaining nanocapsules suspensions 
with a narrow size distribution and good encapsulation efficiency is 
fundamental to maintain their properties, as the control of the drug release 
rate, the overcoming of biological barriers, the increase in the drug solubility 
and oral bioavailability, as well as the protection of the gastrointestinal 
mucosa from the adverse effect of some drugs (Pohlmann et al., 2013).  
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Please insert Figure 3 about here. 
 
A representative in-vitro DFZ release profile from nanocapsules is depicted in 
Figure 4. DFZ-ENC released about 65% of drug after 24 h. DFZ released from 
ENC showed a controlled profile compared to an ethanolic drug solution at the 
same concentration and experimental conditions, which diffusion through the 
dialysis bag was higher than 90% after 24 h (Rigo et al., 2016). However, the 
% of drug release from ENC was higher compared to PCL lipid-core 
nanocapsules, under the same experimental conditions (Rigo et al., 2016). 
This result may be explained by the difference in the viscosity of the oily core 
of nanocapsules and their supramolecular structure. According to these 
properties, DFZ-ENC was considered a suitable formulation model for the 
preparation of 3D printed tablets loaded with nanocapsules. 
 
Please insert Figure 4 about here. 
 
3.4. 3D printed tablets loaded with nanocapsules 
3D printed tablets were prepared using the DFZ-loaded nanocapsules and the 
different delivery devices prepared from EUD or PCL filaments. Their 
physicochemical properties are shown in Table 3. 
 
Please insert Table 3 about here. 
Their physical properties (dimensions and weight) were similar to the original 
devices (differences lower than 5%), except the T-ERL-M. T-ERL-M showed a 
mean weight corresponding to about 75 % of the original device. The highest 
erosion index of these tablets can explain this decrease, which was close to 
30% and in agreement with the percentage of water-soluble components in 
their composition (20% Mannitol + 10% PEG 6000). Overall, these data 
showed that soaking the 3D printed devices in the DFZ-ENC suspension does 
not change their main original physical properties, except the final mass, 
which may depend on their composition and subsequently their erosion 
properties.  
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The swelling index is a property that might have an important influence on the 
proposed approach, as it may be related to the amount of water (and 
nanoparticles) absorbed by the 3D printed devices. Swelling indices were 
dependent on the material of the 3D printed devices (p < 0.05, Two-Way 
ANOVA). Tablets prepared from EUD RL100® devices showed the highest 
swelling indices, which can be explained by the nature of this polymer. It is a 
water-insoluble, highly permeable, ammonium methacrylate copolymer with 
10% of functional quaternary ammonium group, with known swelling 
properties (Rowe et al., 2009). The channelling agent (mannitol) had an 
additional influence on the swelling index of tablets prepared from EUD 
RL100® devices. Tablets prepared with mannitol showed a higher erosion 
index compared to those prepared with microcrystalline cellulose (p ≤ 0.05). 
On the other hand, tablets prepared from PCL devices showed very low 
swelling and erosion indices, regardless of the presence of the channelling 
agent, which can be explained by the low water-solubility of PCL along with its 
non-swelling property (Rowe et al., 2009; Pohlmann et al., 2013). The low 
erosion indices might suggest that the amount of the channelling agent was 
not enough to promote the efficient water intake into inner compartment of 
PCL tablets. Therefore, 3D printed tablets were produced from PCL filaments 
containing 30% instead of 20% of mannitol, called as T-PCL-M’. They showed 
higher erosion and swelling indices (13.20 ± 0.75 % and 18.92 ± 1.26 %, 
respectively) compared to tablets containing 20 % of the mannitol (p ≤ 0.05). 
Their mean weight, diameter and height were 0.2642 ± 0.0067 mg, 9.68 ± 
0.02 mm, and 3.54 ± 0.03, respectively. 
The erosion index due to the solubilisation of the water-soluble components 
was confirmed by spatial compound distribution analysis with confocal Raman 
microscopy. 3D printed EUD tablets prepared with mannitol did not show the 
presence of mannitol in their structure (blue colour) after the loading of the 
drug nanocarriers (Figure 5A), due to the release of mannitol from tablets 
during the soaking process in the nanocapsules suspension. Only the 
presence of Eudragit (red color) could be detected. On the other hand, when 
mannitol was replaced by the water insoluble component (MCC), EUD tablets 
showed the presence of MCC (blue colour) in their structure (Figure 5B) also 
after soaking. The same behaviour was observed for PCL tablets (data not 
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shown). Unfortunately, the strong scattering capabilities of the excipients in 
combination with the huge concentration difference of excipients versus drug-
loaded nanocapsules impeded detection of nanocapsules on the tablet 
surface by confocal Raman microscopy, regardless of the formulation. 
Consequently, liquid chromatography and scanning electron microscopy 
analysis were carried out to evaluate the drug content and the presence of the 
nanoparticles in the tablets structure, respectively. 
Please insert Figure 5 about here. 
 
The amount of drug per tablet (drug content) and drug loading (%) were highly 
dependent on the polymer used (Two-way Anova, p ≤ 0.05). Tablets prepared 
from the EUD RL100® devices showed higher drug content and drug loading 
than tablets prepared from PCL devices, probably due to their higher swelling 
indices, as previously discussed. On the other hand, the presence of the 
channelling agent did not show any influence on the drug content, while its 
influence can be clearly observed on the % of drug loading (p ≤ 0.05). While 
the channelling agent in PCL tablets did not affect the drug loading, the 
increase of mannitol to 30% (T-PCL-M’) was able to increase 1.7x the drug 
loading (0.1040 ± 0.0048 %). This finding corroborates the erosion and 
swelling indices, as previously discussed.  
All drug loadings (%) were higher than expected. It would be expected that 
the drug loading would be related to the volume of the DFZ-ENC suspension 
absorbed by the 3D printed device during the soaking process. From this 
point of view, the expected drug loading values were calculated considering 
the drug content of the DFZ-ENC, the volume absorbed and the final mass of 
the tablet. The following expected drug loading (%) were estimated for T-
EUD-M, T-EUD-A, T-PCL-M and T-PCL-A, as: 0.1015 ± 0.0057 %, 0.0810 ± 
0.0053 %, 0.0047 ± 0.0003 %, and 0.0057 ± 0.0001 %, respectively. 
However, experimental findings showed higher drug loading (%) than the 
expected (about 2x for the T-EUD-M and T-EUD-A, 14x for T-PCL-M and 11x 
for the T-PCL-A). The drug content was not only affected by passive 
absorption of the DFZ-ENC (volume intake), but the nanoparticles themselves 
appear to trigger drug movement towards the tablet. This effect was more 
pronounced for T-PCL, probably due to its lesser swelling properties, 
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highlighting the important role of the uptake mechanism governed by the 
nanocapsules. This mechanism should be investigated further in future 
studies taking into account particles with different surfaces (cationic, anionic 
and non-ionic surfaces) and loaded with different drugs and/or labelled-
markers. 
In addition, loading the EUD 3D printed tablets with DFL-ENC using the 
proposed approach produce tablets with higher drug loading (%) compared to 
the previous report for tablets containing nanocapsules (Friedrich et al, 2010a; 
Friedrich et al., 2010b) where the tablets were prepared by wet granulation 
with a drug loading (%) of 0.082 %. PCL tablets loaded with 30% of mannitol 
also showed a higher drug loading compared to this previous report. These 
data are particularly important when it is considered that the PCL delivery 
devices are composed of biodegradable and biocompatible materials, 
approved for systemic use, allowing their future design in the shape of 
subcutaneous or intrauterine implants for drug delivery.  
For a deeper evaluation of the effects of the soaking time, 3D printed tablets 
loaded with nanocapsules and prepared from ERL-M devices were chosen to 
evaluate the influence of soaking time on their properties due to their higher 
drug loading. Table 4 shows the results for tablets prepared with different 
soaking time (4 and 12 h), which shall be compared to those in Table 3 for T-
ERL-M, considered as T-ERL-M24h as well as T-ERL-M100%. 
 
Please insert Table 4 about here. 
 
The swelling and erosion indices, drug content and drug loading were 
dependent on the soaking time (one-way Anova, p < 0.05). The longer the 
soaking time, the higher the drug content and drug loading. This result can be 
explained by the time necessary for the complete swelling and erosion of the 
3D printed device, reaching values close to 205% and 29% after 24 h, 
respectively, as well as by improving the inflowing of the nanocapsules. 
A linear correlation was obtained considering all the evaluated soaking time 
(4, 8 and 12 h) and the drug content of tablets (y = 0.0164x + 0.1378, r2 = 
0.9211) or the soaking time (4, 8 and 12 h) and the drug loading (y = 0.0084 + 
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0.0277, r2 = 0.9739), suggesting that this property can be used to tailor the 
desired amount of the drug per tablet in a treatment design.  
Furthermore, the infill percentage has an important influence on drug loading. 
3D printed tablets prepared from 3D printed EUD-M devices with 50% infill 
percentage (T-ERL-M50%) showed a reduced mean weight (0.2070 ± 0.0055) 
compared to T-ERL-M, as expected. Their physical dimensions (diameter and 
height) and drug content (0.4808 ± 0.0137 mg per tablet) were similar to T-
ERL-M. Therefore, the reduced infill percentage led to an increase in the drug 
loading (0.2744 ± 0.0161 %) compared to them (p < 0.05). The reduced infill 
percentage allows the obtaining of 3D printed tablets loaded with 
nanocapsules using lower amount of excipients, a lighter drug dosage form 
and higher drug loading. This feature is particularly important taking into 
account that the control of the infill percentage is not possible in the 
conventional tableting methods.  
DSC analyses were also carried out on the tablets to confirm the hypothesis 
about the dissolution of the channelling agent during the soaking process. 
Results are depicted in Figure 6. Thermograms of tablets printed from EUD 
filaments (T-ERL-M, T-ERL-M50% and T-ERL-A) show the glass transition 
temperature of Eudragit of about 56 °C. T-ERL-M shows a less prominent 
endothermic peak at 167 °C compared to its original filament (Figure 2B), an 
additional peak at 157 °C and absence of the endotherm peak at about 60 °C. 
On the other hand, the T-ERL-M50% does not show any endothermic peak at 
171 °C and a very small signal at 57 °C. These data can be explained by the 
solubilisation of mannitol (mp of 171 °C) as well as the PEG 6000 (mp 63 °C) 
during the soaking step. In addition, T-ERL-A does not show any significant 
endothermic peak, except the Eudragit glass transition temperature, 
suggesting the solubilisation of PEG 6000 during the soaking process. These 
data are in agreement with the erosion indices previously discussed, which 
were in the following descending order: T-EUD-M50% > T-EUD-M > T-EUD-A. 
However, the presence of the additional endothermic peak around 157 °C in 
the thermogram of the T-ERL-M was unexpected. This thermal event can be 
explained by the re-crystallisation of mannitol in another polymorphic form 
(the metastable delta form) during the heating process (Burger et al., 2000). 
As this thermal event at 157 °C was observed in the thermogram of T-ERL-M 
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before the soaking process (data not shown) it means it is formed during 
extrusion through the printing nozzle, as the printing temperature (170 °C) 
was close to the melting point of mannitol. Regarding the PCL tablets, an 
endothermic peak at 63 °C was observed for all tablets, which is the PCL 
melting point. Formulations prepared with 20% and 30% of mannitol (T-PCL-
M and T-PCL-M’, respectively) showed the presence of an endothermic peak 
at 171 °C, confirming the presence of residual mannitol even after the soaking 
process and explaining the lower aqueous medium intake for EUD tablets.  
 
Please insert Figure 6 about here. 
 
The morphology of the tablets was analysed by SEM. SEM images of 4 
formulations (T-ERL-M, T-ERL-A, T-PCL-M’, and T-PCL-A) are shown in 
Figure 7 for their surface and cross-section. The images confirm the presence 
of nanoparticles with diameters between 100 and 200 nm on the surface as 
well as in the inner compartment of the 3D printed tablets loaded with 
nanocapsules, regardless of the polymeric component or the presence of the 
channelling agent in the original filament. 
 
Please insert Figure 7 about here. 
 
The influence of the main polymeric component of the delivery device (ERL or 
PCL), the presence of the channelling agent and the infill percentage was 
evaluated on the drug release profile of the tablets. The following formulations 
were evaluated: T-ERL-M, T-ERL-M50%, T-ERL-A, T-PCL-M’, T-PCL-A (Fig 8). 
The data were modelled according to the monoexponential equation (Table 
5), showing a good regression coefficient (r > 0.99) in order to compare their 
release rates. 
 
Please insert Figure 8 about here. 
 
Please insert Table 5 about here. 
 
 21 
The influence of the main component of the tablets (ERL or PCL) was 
dependent on the presence of the channelling agent. In the presence of the 
channelling agent, ERL tablets (T-ERL-M) showed a faster release constant 
compared to PCL tablets (T-PCL-M). On the other hand, the release rates 
were similar for those prepared without the channelling agent (T-ERL-A or T-
PCL-A). These data may be explained by the higher swelling and erosion 
indices showed by the tablets prepared with ERL and the channelling agent, 
as previously discussed (Table 2), facilitating easier access of the release 
medium to their inner structure and subsequently increasing the drug release 
rate. For ERL tablets, a faster release profile was observed for the tablets 
containing the channelling agent (T-ERL-M) compared to that without it (T-
ERL-A). Although both formulations are composed of a swellable polymer, 
their swelling indices in aqueous medium are significantly different (about 
200% and 150% for T-ERL-M and T-ERL-A, respectively), as previously 
shown (Table 2). Moreover, the infill percentage has an additional influence of 
the drug release from T-ERL-M. Tablets prepared from the delivery devices 
containing 50% of infill percentage showed the fastest drug release. This 
result can be explained by the easier and faster access of the dissolution 
medium to the whole structure of the 3D printed tablets, in agreement with a 
previous report on the modulation of the release of a non-encapsulated 
substance (fluorescein) by changing the infill percentage of 3D printed PVA 
tablets (Goyanes et al., 2014).  
Conversely, 3D printed PCL tablets did not show any influence of the 
channelling agent on their drug release profiles (Figure 6B) and release 
constants (Table 6), which can by explained by the low swelling and erosion 
properties of these tablets. Moreover, the half-life time for the different 
formulations, that means the time for the release of 50% of the drug, was 
calculated as 20.67 ± 0.99 min, 12.93 ± 0.60 min, 10.79 ± 0.16 min, 23.75 ± 
0.63 min, and 22.10 ± 1.47 min for T-ERL-A, T-ERL-M, T-ERL-M50%, T-PCL-A, 
and T-PCL-M. These data confirm the faster release rate by the lower infill 
percentage, followed by the ERL tablets containing the channelling agent (T-
ERL-M). The ERL tablets and PCL tablets without the channelling agent 
showed the most prolonged drug release.  
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From the release data discussed above, it is evident that the release 
behaviour is not only influenced by the drug release from the nanocarrier, but 
also by the tablet composition and its properties. In this proposed approach, 
the drug is nanoencapsulated and the release behaviour may be a 
combination of different mechanisms: the release of the drug from the 
nanocapsules followed by diffusion of the drug and/or the release of the 
nanocapsules from the tablets followed by the drug release from the 
nanocarriers. The release data were fitted to the Power Law (r > 0.99) to 
understand the mechanisms underlying the drug release from the 3D printed 
tablets. Their polymeric content, infill percentage and the presence of the 
channelling agent did not influence the mechanism of drug release, which 
could be described as anomalous transport (Supplementary Information - S1), 
considering their cylindrical geometry (Siepmann and Peppas, 2012). The 
drug release from the 3D printed tablets may be governed by the 
superposition of the Fickian diffusion and the case-II transport, where the 
relaxation of the polymer chains by the water imbibition into the systems 
would be the rate-controlling step.  
It was also important to determine whether the nanocapsules themselves 
were released during dissolution testing. The experiment was carried out 
based on the particle size profile showed by the release medium after 1, 4, 8 
and 24 h (Figure 9). Ultrapure water without any additives was used as the 
medium in order to avoid any interference. Results were analysed considering 
the distribution analysis, since the samples were too polydisperse for 
cumulant analysis (Mastersizer v. 3.0, Malvern Instruments Ltd., UK).  
 
Please insert Figure 9 about here. 
 
Particle size release was dependent on the main polymeric component of the 
tablets as well as the presence of the channelling agent. ERL tablets 
containing the channelling agent showed the highest similarity of the particle 
size distribution compared to the original suspension. This similarity increases 
with time, if the data after 1h, 4h and 8h are compared. This result is in 
agreement with their faster drug release, supporting the importance of the 
improved water intake by tablets. Regarding the PCL, a closer similarity to the 
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original suspension was also observed in presence of the channelling agent 
as a function of time. The intensity (%) of the size distribution was lower for 
PCL tablets compared to ERL tablets, which may be related to the lower 
amount of particles in the PCL tablets, in agreement with the drug content 
data (showed in Table 4).  
Taking all the data discussed above into account, nanocapsules embedded in 
3D printed materials may be a strategy to improve the oral or implantable 
systemic delivery of drugs. The conjugating of nanotechnology and 3D 
printing technique may bring their advantages together, using a personalised 
method of manufacture to tailor the drug release and the dose as well as 
using a nanocarrier to control the drug release rate, to increase drug solubility 
and bioavailability, its chemical stability, or preventing its immediate contact 
with the gastrointestinal mucosa or tissue.  
 
 
4. Conclusion 
The present study widens the approaches to producing 3D printed tablets, as 
drug delivery systems. It represents the first report on conjugating 
nanotechnology and a 3D printing to produce innovative nanomedicines. 
Polymeric nanocapsules were successfully loaded in FDM printed devices 
prepared from novel printable polymeric filaments. The type of the polymer, 
the presence of a channelling agent and the infill percentage all had an 
important influence on the drug loading and drug release profiles from the 
tablets. Moreover, it is an original strategy to convert nanocapsules liquid 
suspensions into solid drug dosage forms with improved drug loading. As a 
proof of concept, this study proposed a new platform for the development of 
oral dosage forms, or even biodegradable implants, with tailored dose and 
drug release profiles, as personalised medicines.   
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Figure Captions 
 
Figure 1. Schematic representation of the proposed process to prepare 3D 
printed tablets loaded with polymeric nanocapsules. HME: Hot melt 
extrusion. FDM: Fused deposition modelling. 
 
Figure 2. DSC thermograms for (A) raw materials: Eudragit RS100® 
(EUDRS100), Poly(ε -caprolactone) (PCL), Poly(ethylene)glycol 6000 
(PEG 6000), mannitol, and microcrystalline cellulose (MCC); (B) EUD 
filaments (FIL) and their physical mixtures (PM): FIL-EUD-M, PM-EUD-M, 
FIL-EUD-A, and PM-EUD-A; (C) PCL filaments (FIL) and their physical 
mixtures (PM): FIL-PCL-M, PM-PCL-M, FIL-PCL-M’, PM-PCL-M’, FIL-
PCL-A, PM-PCL-A. 
 
Figure 3. Particle size distribution of formulation DFZ-ENC by (A) Laser 
Diffraction and (B) Dynamic Light Scattering. Results represent three 
independent batches. 
 
Figure 4. In vitro deflazacort release profile from Eudragit RS100® 
nanocapsules (DFZ-ENC) (n = 3).  Results are expressed as mean ± 
standard deviation. 
 
Figure 5. False-color Raman images of 3D printed tablets: (A) T-ERL-M and 
(B) T-ERL-A. Eudragit RL (ERL) is depicted in red, while mannitol (M, 
figure A) or microcrystalline cellulose (A, figure B) are depicted in blue in 
the respective image. 
 
Figure 6. DSC thermograms for 3D printed tablets loaded with nanocapsules 
prepared with EUD (T-EUD-M, T-EUD-M50% and T-EUD-A) and PCL (T-
PCL-M, T-PCL-M’ and T-PCL-A). ERL: Eudragit RL100; PCL: Poly(e-
caprolactone); M: Mannitol A: Avicel PH 301, MCC. 
 
Figure 7. SEM images of surface (left side) and cross sections (right side) of 
the following tablets loaded with nanocapsules: (A) T-ERL-M, (B) T-ERL-
A, (C) T-PCL-M’, and (D) T-PCL-A (at 50,000X magnification, scale bar: 1 
m, EHT 10 kV). Arrows indicate nanoparticles. ERL: Eudragit RL100; 
PCL: Poly(e-caprolactone); M: Mannitol A: Avicel PH 301, MCC. 
 
Figure 8. DFZ release profile (n = 3) from (A) 3D printed tablets prepared from 
EUD devices and (B) 3D printed tablets prepared from PCL devices. 
Results are expressed as mean ± standard deviation. ERL: Eudragit 
RL100; PCL: Poly(e-caprolactone); M: Mannitol A: Avicel PH 301, MCC. 
 
Figure 9. Particle size distribution by DLS of 3D printed tablets loaded with 
nanocapsules after (A) 1h, (B) 4h, (C) 8h, and (D) 24h of immersion in 
ultrapure water. DFZ-ENC represents the original particle size distribution 
of the liquid suspension. ERL: Eudragit RL100; PCL: Poly(e-
caprolactone); M: Mannitol A: Avicel PH 301, MCC. 
